EUVIMEDEUVIMED entdecken
Open Access

Distinct relapse pattern across molecular ependymoma types

Denise Obrecht-Sturm iD, Melanie Schoof, Alicia Eckhardt, Martin Mynarek iD, Mark R Gilbert iD, Kenneth Aldape, Terri S Armstrong, Vijay Ramaswamy iD, Michael Bockmayr, Katja von Hoff, Gudrun Fleischhack, Jonas E Adolph und 15 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Denise Obrecht-Sturm und 26 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Ependymoma, Neoplasm Recurrence, Local, DNA Methylation, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft, Collaborative Ependymoma Research Network, German Children Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ependymoma (EPN) is not a uniform disease but represents different disease types with biological and clinical heterogeneity. However, the pattern of when and where different types of EPN relapse is not yet comprehensively described.

Methods

We assembled 269 relapsed intracranial EPN from pediatric (n = 233) and adult (n = 36) patients from European and Northern American cohorts and correlated DNA methylation patterns and copy-number alterations with clinical information.

Results

The cohort comprised the following molecular EPN types: PF-EPN-A (n = 177), ST-EPN-ZFTA (n = 45), PF-EPN-B (n = 31), PF-EPN-SE (n = 12), and ST-EPN-YAP (n = 4). First relapses of PF-EPN-B (PF: posterior-fossa) and PF-EPN-SE (SE: subependymoma) occurred later than of PF-EPN-A, ST-EPN-YAP (ST: supratentorial), or ST-EPN-ZFTA (median time to relapse: 4.3 and 6.0 years vs. 1.9/1.0/2.4 years; P < .01). Metastatic or combined recurrences in PF-EPN-B and -A more often involved the spinal cord than in ST-EPN-ZFTA (72.7% and 40.0 vs. 12.5%; P < .01). No distant relapses were observed in ST-EPN-YAP (n = 4) or PF-EPN-SE (n = 12). Post-relapse survival (PRS) was poor for PF-EPN-A and ST-EPN-ZFTA (5-year PRS: 44.5% ± 4.4%/47.8% ± 9.1%), whereas PF-EPN-B and PF-EPN-SE displayed a 5-year PRS of 89.5% ± 7.1%/90.0% ± 9.5% (P = .03). However, 10-year PRS for PF-EPN-B dropped to 45.8% ± 17.3%. Neither between the radiation field and relapse pattern nor between the radiation field and spinal involvement at relapse an impact was identified. Notably, all patients with relapsed ST-EPN-YAP did not receive upfront radiotherapy but were successfully salvaged using irradiation at relapse.

Conclusions

Relapse patterns of specific EPN types are different. Future clinical trials, treatment adaptions, duration of surveillance, and diagnostics should be planned to incorporate entity-specific relapse information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpendymomaNeoplasm Recurrence, LocalDNA MethylationBrain NeoplasmsBiomarkers, TumorHumansFemaleMaleChildAdolescentAdultChild, PreschoolYoung AdultMiddle AgedFollow-Up StudiesPrognosisInfantSurvival RateDNA Copy Number VariationsAged

Stichwörter der Autor:innen

ependymomametastaticrecurrencerelapse

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Research Institute Children's Cancer Center Hamburg, Hamburg, Germany.
  • Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.

ORCID-Profile: Denise Obrecht-Sturm, Martin Mynarek, Mark R Gilbert, Vijay Ramaswamy, Stefan M Pfister, Richard Drexler, Monika Warmuth-Metz, Christine Haberler, Ulrich Schüller

Förderung

  • Deutsche Forschungsgemeinschaft
  • Collaborative Ependymoma Research Network
  • German Children Cancer Foundation
  • Neuroradiology and Neuropathology of the German

Zitieren

APA

Obrecht-Sturm, D., Schoof, M., Eckhardt, A., Mynarek, M., Gilbert, M. R., Aldape, K., Armstrong, T. S., Ramaswamy, V., Bockmayr, M., von Hoff, K., Fleischhack, G., Adolph, J. E., Tippelt, S., Pfister, S. M., Pajtler, K., Sturm, D., Drexler, R., Ricklefs, F. L., Stepien, N., …, & Schüller, U. (2025). Distinct relapse pattern across molecular ependymoma types. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae166

Vancouver

Obrecht-Sturm D, Schoof M, Eckhardt A, Mynarek M, Gilbert MR, Aldape K, et al. Distinct relapse pattern across molecular ependymoma types. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae166

BibTeX
@article{ObrechtSturm2025,
  author = {Obrecht-Sturm, Denise and Schoof, Melanie and Eckhardt, Alicia and Mynarek, Martin and Gilbert, Mark R and Aldape, Kenneth and Armstrong, Terri S and Ramaswamy, Vijay and Bockmayr, Michael and von Hoff, Katja and Fleischhack, Gudrun and Adolph, Jonas E and Tippelt, Stephan and Pfister, Stefan M and Pajtler, Kristian and Sturm, Dominik and Drexler, Richard and Ricklefs, Franz L and Stepien, Natalia and Gojo, Johannes and Pietsch, Torsten and Warmuth-Metz, Monika and Kortmann, Rolf and Timmermann, Beate and Haberler, Christine and Rutkowski, Stefan and Schüller, Ulrich},
  title = {Distinct relapse pattern across molecular ependymoma types},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae166}
}
Kostenlos starten →